Shots:
- Formosa has entered into an exclusive licensing agreement with Rxilient to commercialize APP13007, a 0.05% clobetasol propionate ophthalmic suspension for the treatment of inflammation & pain after ocular surgery
- As per the deal, Rxilient will gain exclusive rights to commercialize the suspension across key ASEAN markets, incl. Indonesia, Philippines, Singapore, & Thailand, with the deal including upfront, regulatory, & sales milestones, though financial terms were not disclosed
- APP13007 (BID for 14 days) is a superpotent clobetasol propionate formulation built on Formosa’s APNT nanoparticle platform & received FDA approval in 2024
Ref: PRNewswire | Image: Formosa & Rxilient | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
